<DOC>
	<DOCNO>NCT00038428</DOCNO>
	<brief_summary>The purpose study determine effectiveness safety TLK286 give intravenously every week treatment patient advanced ovarian cancer resistant platinum-based chemotherapy .</brief_summary>
	<brief_title>Phase 2 Study TLK286 Platinum Resistant Advanced Epithelial Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Histologic diagnosis ovarian cancer Recurrent persistent disease follow primary therapy Measurable disease Prior treatment least one three prior chemotherapy regimen Resistant refractory platinumbased chemotherapy At least 18 year age Good performance status ( ECOG 0 1 ) Adequate liver , renal bone marrow function Exclusion criterion Pregnant currently breast feed Treatment chemotherapy immunotherapy within four week Prior radiation whole pelvis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>